CytoSorbents Corporation (CTSO)

[BG Man]

raptorjockey-
Please see my previous post (#14364) referencing Bellicum Pharmaceuticals.
My understanding from reading the medical literature is that the use of
CAR-T therapy is far from an exact science with varying degrees of side
effects of which cytokine storm is at the extreme. Bellicum has tried to
gain better control of the process by administration of a product (rimiducid)
which to some degree controls the activation of the CAR-T cells thus elimination or reducing some of the side effects. In the very small series
outlined in the article in my previous post, there were no episodes of
cytokine storm. As progress is made in CAR-T therapy, the treatment will
most likely become more refined with better control of the process and a
reduction and/or elimination of some of the side effects. The role of
cytosorb in CAR-T therapy will depend to some degree on how well the drug
companies are able to refine the treatment and reduce the side effects.
Regarding your question as to why there seems to be a lack of interest
in cytosorb from the leaders of CAR-T research; in medicine, everything
happens slower than you anticipate.